NCT01602562 - Valaciclovir Hydrochloride Phase III for Hematopoietic Stem Cell Transplantation Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 7, 2012

Primary Completion Date

May 1, 2013

Study Completion Date

May 24, 2013

Conditions

Herpes Simplex

Interventions

DRUG

VACV tablets (Adults or pediatrics) or granules (pediatrics)

A white to slightly yellowish white film coated tablet contains 556 mg of valaciclovir hydrochloride (500 mg of valaciclovir)). VACV granules have no or slightly specific odor.

Trial Locations (11)

446-8602

GSK Investigational Site, Aichi

453-8511

GSK Investigational Site, Aichi

466-8560

GSK Investigational Site, Aichi

734-8551

GSK Investigational Site, Hiroshima

650-0047

GSK Investigational Site, Hyōgo

654-0081

GSK Investigational Site, Hyōgo

890-8520

GSK Investigational Site, Kagoshima

259-1143

GSK Investigational Site, Kanagawa

594-1101

GSK Investigational Site, Osaka

339-8551

GSK Investigational Site, Saitama

162-8655

GSK Investigational Site, Tokyo